Pharmaceutical Intermediate Efavirenz Powder Antiretroviral Efavirenz

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-efavirenz
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Efavirenz
• CAS No: 154598-52-4
• Molecular Formula: C14h9clf3no2
• Molecular Weight: 315.68 G/Mol
• Description: White to off-White Crystalline Powder
• Identification: Retention Time Matches Reference Std.
• Water Content: ≤ 0.5%
• Tailing Factor: ≤ 2.0
• Rsd for Standard Injections: ≤ 2.0%
• Heavy Metals (Ppm): ≤ 10 Ppm
• Melting Point: 138 – 142°c
• Sulphated Ash: ≤ 0.1%
• Dissolution: ≥ 85% in 45 Min
• Column: C18 (250 mm × 4.6 mm, 5 µm)
• Flow Rate: 1.0 Ml/Min
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS
• Origin: Xian
• Production Capacity: 30 Kg/Month

Product Description

Pharmaceutical Intermediate efavirenz Powder Antiretroviral efavirenz

Product Description

Product Details

Product Name	Efavirenz
Apperance	White to off-white crystalline powder
CAS	154598-52-4
MF	C14H9ClF3NO2
MW	315.68 g/mol

Efavirenz (Efavirenz, CAS number: 154598-52-4) is a non nucleoside reverse transcriptase inhibitor (NNRTI) with the molecular formula C14H9ClF3NO2 and a molecular weight of 315.675. This compound is a white to off white crystalline powder with a melting point of 139-141 ° C. It is easily soluble in  and ethanol, but has poor water solubility. Its structure contains a chiral center. Efavirenz needs to be stored at low temperatures (<0 ° C) to avoid degradation and has high lipid solubility.

Application&Function

Efavirenz is mainly used to treat HIV-1 infection by selectively inhibiting viral reverse transcriptase (Ki=2.93 nM) to block virus replication. It can significantly reduce viral load when used in combination with other antiretroviral drugs. In addition, studies have shown that Efavirenz is still effective against certain drug-resistant HIV strains and has no significant inhibition on mammalian polymerases, indicating high safety. Its mechanism of action is to bind to the inactive site of reverse transcriptase, non competitively inhibiting RNA dependent DNA synthesis.

Specification

ABOUT US